Trial reportDrug and alcohol dependence2025
Baseline predictors of smoking cessation among individuals with current or past major depressive disorder following treatment with varenicline and intensive behavioral treatment.
Trial report in Drug and alcohol dependence, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
introductionIn a 2 × 2 factorial clinical trial with 300 individuals with current or past major depressive disorder (MDD), varenicline significantly increased smoking cessation, compared to placebo, whereas behavioral activation for smoking cessation yielded similar quit rates compared to standard behavioral treatment. In this secondary analysis, we evaluated whether participant characteristics at baseline predicted abstinence or moderated the effects of behavioral treatment or pharmacotherapy on abstinence.
methodsThe sample was racially and socioeconomically diverse and spanned varied psychiatric presentations: 49 % of participants had current MDD, 44 % had other mental health disorders, and only 27 % were being treated for their depression. Self-reported 7-day point prevalence abstinence at end-of-treatment (EOT; Week 14) and long-term follow-up (Week 27) was confirmed using breath carbon monoxide (≤6 parts per million).
resultsIn a logistic regression model, greater likelihood of abstinence at EOT was associated with varenicline vs. placebo (OR=5.52, 95 % CI=2.62-11.60), lower cigarette dependence (OR=0.42, 95 % CI=0.19-0.90), and fast nicotine metabolism (OR=1.64, 95 % CI=1.06-2.54). In second logistic regression model, greater likelihood of Week 27 abstinence was associated with varenicline vs placebo (OR=3.06, 95 % CI=1.32-7.07) and fast nicotine metabolism (OR=2.06, 95 % CI=1.20-3.54). None of the baseline factors interacted with behavioral or pharmacological treatment to predict abstinence at either time point.
conclusionsVarenicline should be a primary treatment consideration for individuals with MDD. Stable psychiatric status is not required for favorable treatment outcome. Further effort is needed to identify behavioral interventions that can be added to varenicline to improve quit rates for individuals with MDD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.